Pharmacy Support Improved ATTR-CM Medication Adherence

Specialty pharmacists helped manage symptoms and treatment consistency for adults with ATTR-CM.

Updated on Oct. 10, 2026 in Heart Disease

Rows of amber pharmacy bottles and clear medical vials neatly arranged on a clean white clinical dispensing counter. — Specialty pharmacy interventions, including regular refill coordination and symptom monitoring, helped patients maintain a 97.9% adherence rate for ATTR-CM therapy. AI Illustration. Upload story photo >

Live Poll

Do you believe regular pharmacist check-ins help you better manage your long-term health medications?

Pharmacist interventions, including medication refills and symptom tracking, supported high adherence rates for patients with ATTR-CM. These findings were shared in research posters presented in September 2026.

Why it matters

Managing ATTR-CM requires consistent therapy, and frequent pharmacist touchpoints ensure patients stay on track while receiving timely medical attention for worsening symptoms. This care model highlights the role of pharmacy liaisons in supporting complex treatment regimens for older adults.

A study of 439 patients found a 98% mean proportion of days covered for medication, while a patient perception analysis of 1032 adults showed 74% reported no change in their feelings toward treatment. These findings represent observational data from recent pharmacy interventions.

The players

Pharmacy Liaisons

Healthcare professionals who manage medication access and provide ongoing clinical support for patients on complex therapies.

The details

Specialty pharmacy teams assist patients by coordinating medication refills every 30 to 90 days and conducting clinical reassessments every 2 to 10 months. When pharmacists identify worsening symptoms, they escalate these concerns to providers, who accepted 90% of those reports. This proactive communication bridge helps maintain a mean adjusted adherence rate of 97.9% over an average of 603.5 days of therapy.

May 2019 to February 2026 marked the patient perception analysis period.
November 2025 to April 2026 was the pharmacist intervention study period.
September 22-25, 2026, was when the research posters were presented.

Health Landscape

This research aligns with the evolution of ATTR-CM clinical management standards toward integrated, multidisciplinary care models. It highlights a shift in how pharmacy support is measured alongside traditional patient perceptions in the treatment of rare systemic conditions.

If you are managing ATTR-CM, consider discussing the frequency of your pharmacy touchpoints and symptom-reporting protocols with your care team. Maintaining a high proportion of days covered is key to treatment success, and your pharmacist can be a valuable partner in tracking symptom changes.

The takeaway

The data suggests that regular interaction with specialty pharmacy teams helps maintain medication adherence for those with ATTR-CM. Discuss with your physician whether your current pharmacy support plan includes routine clinical reassessments to monitor for potential symptom shifts.